These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31754711)

  • 1. In vitro and in vivo properties of therapeutic oligonucleotides containing non-chiral 3' and 5' thiophosphate linkages.
    Duschmalé J; Hansen HF; Duschmalé M; Koller E; Albaek N; Møller MR; Jensen K; Koch T; Wengel J; Bleicher K
    Nucleic Acids Res; 2020 Jan; 48(1):63-74. PubMed ID: 31754711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides.
    Østergaard ME; De Hoyos CL; Wan WB; Shen W; Low A; Berdeja A; Vasquez G; Murray S; Migawa MT; Liang XH; Swayze EE; Crooke ST; Seth PP
    Nucleic Acids Res; 2020 Feb; 48(4):1691-1700. PubMed ID: 31980820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages.
    Wan WB; Migawa MT; Vasquez G; Murray HM; Nichols JG; Gaus H; Berdeja A; Lee S; Hart CE; Lima WF; Swayze EE; Seth PP
    Nucleic Acids Res; 2014 Dec; 42(22):13456-68. PubMed ID: 25398895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides.
    Iwamoto N; Butler DCD; Svrzikapa N; Mohapatra S; Zlatev I; Sah DWY; Meena ; Standley SM; Lu G; Apponi LH; Frank-Kamenetsky M; Zhang JJ; Vargeese C; Verdine GL
    Nat Biotechnol; 2017 Sep; 35(9):845-851. PubMed ID: 28829437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of multiple-turnover capability of locked nucleic acid antisense oligonucleotides in cell-free RNase H-mediated antisense reaction and in mice.
    Yamamoto T; Fujii N; Yasuhara H; Wada S; Wada F; Shigesada N; Harada-Shiba M; Obika S
    Nucleic Acid Ther; 2014 Aug; 24(4):283-90. PubMed ID: 24758560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a Tricyclic P
    Sakamuri S; Liu D; Eltepu L; Liu B; Reboton LJ; Preston R; Bradshaw CW
    Chembiochem; 2020 May; 21(9):1298-1303. PubMed ID: 31863718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of
    Kiełpiński ŁJ; Funder ED; Schmidt S; Hagedorn PH
    Nucleic Acid Ther; 2021 Dec; 31(6):383-391. PubMed ID: 34619060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endosomal Escape of Antisense Oligonucleotides Internalized by Stabilin Receptors Is Regulated by Rab5C and EEA1 During Endosomal Maturation.
    Miller CM; Wan WB; Seth PP; Harris EN
    Nucleic Acid Ther; 2018 Apr; 28(2):86-96. PubMed ID: 29437530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo biophysical properties of oligonucleotides containing 5'-thio nucleosides.
    Islam MA; Waki R; Fujisaka A; Ito KR; Obika S
    Drug Discov Ther; 2016; 10(5):263-270. PubMed ID: 27890900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver.
    Miller CM; Donner AJ; Blank EE; Egger AW; Kellar BM; Østergaard ME; Seth PP; Harris EN
    Nucleic Acids Res; 2016 Apr; 44(6):2782-94. PubMed ID: 26908652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.
    Shen W; De Hoyos CL; Migawa MT; Vickers TA; Sun H; Low A; Bell TA; Rahdar M; Mukhopadhyay S; Hart CE; Bell M; Riney S; Murray SF; Greenlee S; Crooke RM; Liang XH; Seth PP; Crooke ST
    Nat Biotechnol; 2019 Jun; 37(6):640-650. PubMed ID: 31036929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesyl phosphoramidate antisense oligonucleotides as an alternative to phosphorothioates with improved biochemical and biological properties.
    Miroshnichenko SK; Patutina OA; Burakova EA; Chelobanov BP; Fokina AA; Vlassov VV; Altman S; Zenkova MA; Stetsenko DA
    Proc Natl Acad Sci U S A; 2019 Jan; 116(4):1229-1234. PubMed ID: 30622178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and cellular activity of stereochemically-pure 2'-O-(2-methoxyethyl)-phosphorothioate oligonucleotides.
    Li M; Lightfoot HL; Halloy F; Malinowska AL; Berk C; Behera A; Schümperli D; Hall J
    Chem Commun (Camb); 2017 Jan; 53(3):541-544. PubMed ID: 27966701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of guanidine-containing backbone linkages on stereopure antisense oligonucleotides in the CNS.
    Kandasamy P; Liu Y; Aduda V; Akare S; Alam R; Andreucci A; Boulay D; Bowman K; Byrne M; Cannon M; Chivatakarn O; Shelke JD; Iwamoto N; Kawamoto T; Kumarasamy J; Lamore S; Lemaitre M; Lin X; Longo K; Looby R; Marappan S; Metterville J; Mohapatra S; Newman B; Paik IH; Patil S; Purcell-Estabrook E; Shimizu M; Shum P; Standley S; Taborn K; Tripathi S; Yang H; Yin Y; Zhao X; Dale E; Vargeese C
    Nucleic Acids Res; 2022 Jun; 50(10):5401-5423. PubMed ID: 35106589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NAT10 and DDX21 Proteins Interact with RNase H1 and Affect the Performance of Phosphorothioate Oligonucleotides.
    Zhang L; Bernardo KD; Vickers TA; Tian J; Liang XH; Crooke ST
    Nucleic Acid Ther; 2022 Aug; 32(4):280-299. PubMed ID: 35852833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereodifferentiation--the effect of P chirality of oligo(nucleoside phosphorothioates) on the activity of bacterial RNase H.
    Koziolkiewicz M; Krakowiak A; Kwinkowski M; Boczkowska M; Stec WJ
    Nucleic Acids Res; 1995 Dec; 23(24):5000-5. PubMed ID: 8559657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Free-radical ring closure to conformationally locked α-L-carba-LNAs and synthesis of their oligos: nuclease stability, target RNA specificity, and elicitation of RNase H.
    Li Q; Yuan F; Zhou C; Plashkevych O; Chattopadhyaya J
    J Org Chem; 2010 Sep; 75(18):6122-40. PubMed ID: 20738147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of sugar-modified oligonucleotides for antisense therapeutics.
    Prakash TP
    Chem Biodivers; 2011 Sep; 8(9):1616-41. PubMed ID: 21922654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of phosphorothioate oligonucleotides with RNase H1 can cause conformational changes in the protein and alter the interactions of RNase H1 with other proteins.
    Zhang L; Vickers TA; Sun H; Liang XH; Crooke ST
    Nucleic Acids Res; 2021 Mar; 49(5):2721-2739. PubMed ID: 33577678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent gene-specific inhibitory properties of mixed-backbone antisense oligonucleotides comprised of 2'-deoxy-2'-fluoro-D-arabinose and 2'-deoxyribose nucleotides.
    Lok CN; Viazovkina E; Min KL; Nagy E; Wilds CJ; Damha MJ; Parniak MA
    Biochemistry; 2002 Mar; 41(10):3457-67. PubMed ID: 11876654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.